CECO Q1 Earnings Call: Bookings Surge, Power Pipeline Grows Amid Tariff Uncertainty
Environmental solutions provider CECO Environmental (NASDAQ:CECO) reported Q1 CY2025 results beating Wall Street's revenue expectations , with sales up 39.9% year on year to $176.7 million. The company's full-year revenue guidance of $725 million at the midpoint came in 3.5% above analysts' estimates. Its non-GAAP profit of $0.10 per share was 12.2% above analysts' consensus estimates.
Is now the time to buy CECO? Find out in our full research report (it's free).
Revenue: $176.7 million vs analyst estimates of $151.1 million (39.9% year-on-year growth, 17% beat)
Adjusted EPS: $0.10 vs analyst estimates of $0.09 (12.2% beat)
Adjusted EBITDA: $14 million vs analyst estimates of $13.35 million (7.9% margin, 4.9% beat)
The company reconfirmed its revenue guidance for the full year of $725 million at the midpoint
EBITDA guidance for the full year is $95 million at the midpoint, above analyst estimates of $91.51 million
Operating Margin: 35%, up from 6.1% in the same quarter last year
Free Cash Flow was -$15.1 million compared to -$1.9 million in the same quarter last year
Market Capitalization: $905.3 million
CECO Environmental's first quarter performance was driven by record order bookings and continued expansion of its diversified sales pipeline. Management highlighted that bookings reached approximately $228 million, up 57% year over year, with the sales pipeline surpassing $5 billion for the first time. CEO Todd Gleason attributed these results to strong demand across industrial air, water, and energy transition markets, as well as the successful integration of recent acquisitions like Profire Energy. Gleason emphasized, 'The same themes that have been driving CECO's growth over the past year are only reinforced by the stated goals of the current administration.'
Looking ahead, management reconfirmed full-year guidance, pointing to resilient end-market demand and a robust backlog. The leadership team acknowledged external risks, particularly from evolving tariffs and potential inflationary pressures, but outlined measures to mitigate these impacts, such as localized supply chains and contractual pass-through clauses. CFO Peter Johansson noted, 'We have taken early action to address our preliminary assessment of tariff-related inflation and costs,' reinforcing management's focus on operational flexibility and cost containment.
CECO Environmental's management cited diversification, operational agility, and successful M&A as key themes influencing Q1 performance, while also addressing how the company is preparing for tariff-related challenges.
Record Bookings Momentum: The company achieved its highest-ever quarterly bookings, driven by balanced demand across industrial air, water, and energy transition sectors. Management reported no evidence of order pull-forward due to tariffs, with robust pipelines in both North America and international markets.
Acquisition Integration Progress: The Profire Energy acquisition contributed to first quarter growth and exceeded internal expectations for bookings and integration. Management noted that Profire achieved record bookings in Q1 and that cross-selling opportunities are emerging, especially in international oil and gas markets.
Expanding International Presence: CECO's non-U.S. business is approaching half of total operations, with high-growth regions like India, Southeast Asia, and the Middle East demonstrating strong demand. Management described India as having a multi-decade growth opportunity, comparing its current trajectory to China's rapid expansion in earlier decades.
Tariff Mitigation Strategies: Management detailed actions to offset tariff-related costs, including contract structures allowing for cost pass-through, localized supply chains, and targeted price increases. They estimate gross tariff exposure between $3 million and $10 million in 2025 but believe most impacts can be managed without significant margin erosion.
Operational Investment: Additional technical and commercial resources were added to support the enlarged backlog and accelerated sales pipeline. This investment in talent and systems, especially IT infrastructure, is expected to enable continued execution and margin expansion as the business scales.
Management remains focused on executing against a large, diversified backlog and navigating potential tariff and inflationary headwinds while maintaining operational efficiency and sales growth.
Backlog Conversion and Project Mix: The $602 million backlog is expected to convert to revenue over the next 18 months, with a shift toward shorter-cycle projects and a steady flow of long-term, highly engineered solutions. Management believes this mix provides revenue stability and margin visibility.
International Expansion: Growth in emerging markets, particularly India and the Middle East, is anticipated to become a larger revenue contributor. Management views international diversification as a buffer against localized economic uncertainty and policy shifts.
Tariff and Supply Chain Risk Management: Ongoing tariff changes and supply chain inflation are cited as key risks. Management's mitigation plan involves contractual protections, localized sourcing, and proactive pricing actions, but acknowledges that unexpected inflation could still impact profitability.
Rob Brown (Lake Street Capital): Asked about the power sector pipeline and timing of large project bookings. Management responded that over $1 billion in opportunities exist, with most revenue from these bookings expected in 2026 and 2027.
Bobby Brooks (Northland Capital): Inquired if order strength was influenced by customers rushing orders ahead of tariffs. CEO Todd Gleason stated there was no evidence of pull-forward, attributing steady demand to broad sectoral strength.
Aaron Spychalla (Craig-Hallum): Sought clarity on capital expenditure priorities. CFO Peter Johansson said IT infrastructure remains the largest investment, with limited need for new manufacturing assets after the recent divestiture.
Gerry Sweeney (Roth Capital): Asked about the risk of indirect tariff impacts on margins later in the year. Management responded that while direct impacts are manageable, broader inflation and supply chain pass-through costs remain a concern.
Sameer Joshi (H.C. Wainwright): Questioned the pace of future M&A activity. Management indicated a near-term focus on integrating recent acquisitions and reducing leverage, with new deals unlikely before the second half of the year.
Looking forward, the StockStory team will be monitoring (1) the timing and size of power sector contract awards, which could drive step-change revenue growth, (2) the pace of backlog conversion and potential for a quarter with sales above $200 million, and (3) progress on integrating recent acquisitions—especially Profire Energy—along with the effectiveness of tariff mitigation strategies. Shifts in international project mix and any material changes in supply chain costs will also be critical signposts.
CECO Environmental currently trades at a forward P/E ratio of 19.9×. At this valuation, is it a buy or sell post earnings? The answer lies in our free research report.
Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs.
While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Why Iovance Biotherapeutics Stock Dove by Almost 15% This Week
The company's CFO resigned from his position. One law firm wasn't shy about reminding investors of the departure. 10 stocks we like better than Iovance Biotherapeutics › There's nothing like a top-level management departure to get investors worried about a publicly traded company. Investors in biotech stock Iovance Therapeutics (NASDAQ: IOVA) were served a strong reminder of the company's latest executive departure earlier in the week. With that headwind blowing in its face, Iovance's shares lost almost 15% of their value during the week, according to data compiled by S&P Global Market Intelligence. Hagens Berman Sobol Shapiro, one of the numerous law firms currently investigating Iovance's activities, was behind the reminder. It pointed out that CFO Jean-Marc Bellemin stepped down from his post earlier in June. His resignation is effective this coming July 10. The law firm hinted that the cancer-focused biotech company's legal headaches were at least partially responsible for this. It wrote in a press release that "Bellemin's exit comes at a tumultuous time, as the company is grappling with a recent commercial setback for its flagship drug, Amtagvi, and the specter of a class action securities lawsuit." Iovance originally disclosed the CFO's resignation on Friday, June 13 in a tersely worded regulatory filing with the Securities and Exchange Commission (SEC). It said only that Bellemin made the move "to pursue other opportunities." It did not elaborate on this. Besides its legal headaches, Iovance is struggling to produce impressive fundamentals. Although it delivered decent top-line growth -- thanks to Amtagvi, a melanoma drug -- it made quite a drastic cut to its product-revenue guidance for the entirety of this year. I don't think Iovance is in a good place just now. However, Amtagvi still has much potential, and the biotech is a player to watch in the cancer space. It might just be worthy of a buy for investors with a large appetite for risk. Before you buy stock in Iovance Biotherapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Iovance Biotherapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $704,676!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $950,198!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Iovance Biotherapeutics. The Motley Fool has a disclosure policy. Why Iovance Biotherapeutics Stock Dove by Almost 15% This Week was originally published by The Motley Fool Sign in to access your portfolio


Business Insider
3 hours ago
- Business Insider
BBAI vs. CRWV vs. APP: Which Growth Stock Is the Best Pick, According to Wall Street Analysts?
Macro uncertainties, geopolitical tensions, and news on the tariff front have kept the stock market volatile. Despite ongoing uncertainties, analysts remain optimistic about several growth stocks and their potential to generate attractive returns over the long term. Using TipRanks' Stock Comparison Tool, we placed BigBear. ai Holdings (BBAI), CoreWeave (CRWV), and AppLovin (APP) against each other to find the best growth stock, according to Wall Street analysts. Confident Investing Starts Here: Holdings (NYSE:BBAI) Stock Holdings stock has risen more than 31% so far in 2025 and 292% over the past year, as investors are optimistic about the prospects of the data analytics company. BBAI offers artificial intelligence (AI)-powered decision intelligence solutions, mainly focused on national security, defense, and critical infrastructure. The company ended Q1 2025 with a backlog of $385 million, reflecting 30% year-over-year growth. However, there have been concerns about low revenue growth rate and high levels of debt. Looking ahead, the company is pursuing further growth through international expansion and strategic partnerships, while continuing to secure attractive government business. What Is the Price Target for BBAI Stock? Last month, Northland Securities analyst Michael Latimore reaffirmed a Hold rating on BBAI stock but lowered his price target to $3.50 from $4 after the company missed Q1 estimates due to further delays in government contracts. On the positive side, the 4-star analyst noted the solid growth in backlog and management's statement that their strategy is 'beginning to resonate.' On TipRanks, Holdings stock is assigned a Moderate Buy consensus rating, backed by two Buys and two Holds. The average BBAI stock price target of $4.83 indicates a possible downside of 17.3% from current levels. CoreWeave (NASDAQ:CRWV) Stock CoreWeave, a cloud provider specializing in AI infrastructure, is seeing robust adoption for its products. The company, which provides customers access to Nvidia's (NVDA) GPUs (graphics processing units), went public in March. CRWV stock has risen about 300% to $159.99, compared to its IPO (initial public offering) price of $40. Remarkably, CoreWeave delivered a 420% jump in its Q1 2025 revenue to $981.6 million. Moreover, the company ended the first quarter of 2025 with a robust backlog of $25.9 billion. Meanwhile, CoreWeave has entered into lucrative deals, including an expanded agreement of up to $4 billion with ChatGPT-maker OpenAI and a collaboration to power the recently announced cloud deal between Alphabet's Google (GOOGL) and OpenAI. Is CRWV a Good Stock to Buy? Recently, Bank of America analyst Bradley Sills downgraded CoreWeave stock to Hold from Buy, citing valuation concerns following the strong rally after the company's Q1 results. Also, the 4-star analyst expects $21 billion of negative free cash flow through 2027, due to elevated capital expenditure ($46.1 billion through 2027). However, Sills raised the price target for CRWV stock to $185 from $76, noting several positives, including the OpenAI deal and strong revenue momentum. Overall, Wall Street has a Moderate Buy consensus rating on CoreWeave stock based on six Buys, 11 Holds, and one Sell recommendation. At $78.53, the average CRWV stock price target indicates a substantial downside risk of about 51%. AppLovin (NASDAQ:APP) Stock Adtech company AppLovin has witnessed a 301% jump in its stock price over the past year. The company provides end-to-end software and AI solutions for businesses to reach, monetize, and grow their global audiences. Notably, AppLovin's strong growth rates have impressed investors. In Q1 2025, AppLovin's revenue grew 40% and earnings per share (EPS) surged by 149%. Investors have also welcomed the company's decision to sell its mobile gaming business to Tripledot Studios. The move is expected to enable AppLovin to focus more on its AI-powered ad business. However, APP stock has declined more than 12% over the past month due to the disappointment related to its non-inclusion in the S&P 500 Index (SPX) and accusations by short-seller Casper Research. Nonetheless, most analysts remain bullish on AppLovin due to its strong fundamentals and demand for the AXON ad platform. Is APP a Good Stock to Buy Recently, Piper Sandler analyst James Callahan increased the price target for AppLovin stock to $470 from $455 and reaffirmed a Buy rating. While Piper Sandler's checks suggest some weakness in AppLovin's supply-side trends, it remains a buyer of APP stock, with the tech company growing well above its digital ad peers and expanding into new verticals. With 16 Buys and three Holds, AppLovin stock scores a Strong Buy consensus rating. The average APP stock price target of $504.18 indicates 51% upside potential from current levels. Conclusion Wall Street is sidelined on stock, cautiously optimistic on CoreWeave, and highly bullish on AppLovin stock. Analysts see higher upside potential in APP stock than in the other two growth stocks. Wall Street's bullish stance on AppLovin stock is backed by solid fundamentals and strong momentum in its AI-powered ad business. According to TipRanks' Smart Score System, APP stock scores a 'Perfect 10,' indicating that it has the ability to outperform the broader market over the long run.
Yahoo
3 hours ago
- Yahoo
Intrusion Inc. (INTZ) Stock Falls Amid Market Uptick: What Investors Need to Know
Intrusion Inc. (INTZ) closed the most recent trading day at $2.23, moving -5.51% from the previous trading session. This move lagged the S&P 500's daily gain of 0.52%. On the other hand, the Dow registered a gain of 1%, and the technology-centric Nasdaq increased by 0.52%. Heading into today, shares of the company had gained 74.82% over the past month, outpacing the Computer and Technology sector's gain of 9.55% and the S&P 500's gain of 5.95%. The investment community will be paying close attention to the earnings performance of Intrusion Inc. in its upcoming release. The company's earnings per share (EPS) are projected to be -$0.09, reflecting a 83.02% increase from the same quarter last year. Meanwhile, our latest consensus estimate is calling for revenue of $1.8 million, up 23.29% from the prior-year quarter. For the annual period, the Zacks Consensus Estimates anticipate earnings of -$0.36 per share and a revenue of $7.65 million, signifying shifts of +77.91% and +32.56%, respectively, from the last year. It's also important for investors to be aware of any recent modifications to analyst estimates for Intrusion Inc. Recent revisions tend to reflect the latest near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Intrusion Inc. is currently a Zacks Rank #3 (Hold). The Computer - Networking industry is part of the Computer and Technology sector. At present, this industry carries a Zacks Industry Rank of 181, placing it within the bottom 27% of over 250 industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow INTZ in the coming trading sessions, be sure to utilize Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intrusion Inc. (INTZ) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research